Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 28, Issue 25, Pages 2843-2853Publisher
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v28.i25.2843
Keywords
Inflammatory bowel disease; Phenotypes; Outcomes; Concurrent immune-mediated inflammatory diseases
Categories
Ask authors/readers for more resources
This review discusses the pathogenesis, disease phenotypes, and clinical outcomes in IBD patients with concurrent IMIDs. It suggests that having multiple IMIDs can exacerbate the severity of IBD and increase the risk of requiring biologics and related surgeries.
Patients with inflammatory bowel disease (IBD) are more likely to have concurrent immune-mediated inflammatory diseases (IMIDs) than those without IBD. IMIDs have been observed to alter the phenotype and outcomes of IBD in recent studies. Several studies have found that IBD patients with concurrent IMIDs may have more extensive or severe disease phenotypes, and are considered to be at increased risk of requiring biologics and IBD-related surgeries, suggesting that having multiple IMIDs is a poor prognostic factor for IBD. Furthermore, IBD patients with primary sclerosing cholangitis and Takayasu arteritis are reported to have unique endoscopic phenotypes, suggesting concurrent IMIDs can influence IBD phenotype with specific intestinal inflammatory distributions. In this review, we discuss the pathogenesis, disease phenotypes, and clinical outcomes in IBD patients with concomitant IMIDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available